

SEQUANA MEDICAL

Limited Liability Company

Registered office: Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium
VAT BE 0707.821.866 Register of Legal Entities Ghent, section Ghent

<p style="text-align: center;">INVITATION EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING to be held on Friday, 20 December 2024, at 9:00 a.m. (Belgian time)</p>

The holders of securities issued by Sequana Medical NV (the "**Company**") are invited to attend the extraordinary general shareholders' meeting of the Company before a notary public.

GENERAL INFORMATION

Date, hour and venue: The extraordinary general shareholders' meeting will be held on Friday, 20 December 2024 at 9:00 a.m. (Belgian time), at the offices of the Company at Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium, or at such other place as will be indicated at that place at that time. There is an attendance quorum requirement for the items on the agenda of the extraordinary general shareholders' meeting (see also below under "*—Extraordinary General Shareholders' Meeting*"). If the attendance quorum for the items of the agenda of the extraordinary general shareholders' meeting were not to be reached, a second extraordinary general shareholders' meeting will be held for these items on Monday, 6 January 2025 at 9:00 a.m. (Belgian time), unless, as the case may be, decided otherwise on behalf of the board of directors.

Opening of the doors: In order to facilitate the keeping of the attendance list on the day of the extraordinary general shareholders' meeting, holders of securities issued by the Company and their representatives are invited to register as from 8:15 a.m. (Belgian time).

AGENDA

Agenda and proposed resolutions: The agenda and the proposed resolutions of the extraordinary general shareholders' meeting of the Company which, as the case may be, can be amended at the meeting on behalf of the board of directors, are as follows:

1. Submission of reports in relation to the cancellation of the Original Kreos Subscription Rights and the issuance of the New Kreos Subscription Rights

Submission of the following reports in relation to the cancellation of the Original Kreos Subscription Rights and the issuance of the New Kreos Subscription Rights (both as defined below):

- (a) the report of the board of directors of the Company in accordance with Articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code of 23 March 2019 (as amended) (the "**Belgian Companies and Associations Code**") in relation to the proposal, subject to the cancellation of the 875,000 existing and outstanding subscription rights for new shares of the Company, issued by the Company's extraordinary general shareholders' meeting on 10 February 2023 to the benefit of Kreos Capital VII Aggregator SCSp ("**Kreos**") (and its permitted successors and assigns), named the "Kreos Subscription Rights" (hereinafter, the "**Original Kreos Subscription Rights**"), to (i) issue 875,000 new subscription rights for new shares in the Company, named the "New Kreos Subscription Rights" (hereinafter, the "**New Kreos Subscription Rights**"), and (ii) dis-apply, in the interest of the Company and for the purposes of the issuance of the New Kreos Subscription Rights, the preferential subscription right of the existing shareholders of the Company and, as far

as needed, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of Kreos (and its permitted successors and assigns); and

- (b) the report of the statutory auditor of the Company in accordance with Articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code in relation to the proposal, subject to the cancellation of the 875,000 Original Kreos Subscription Rights, to (i) issue 875,000 New Kreos Subscription Rights, and (ii) dis-apply, in the interest of the Company and for the purposes of the issuance of the New Kreos Subscription Rights, the preferential subscription right of the existing shareholders of the Company and, as far as needed, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of Kreos (and its permitted successors and assigns).

2. **Proposal to cancel the Original Kreos Subscription Rights and to issue the New Kreos Subscription Rights to Kreos**

Proposed resolution: The extraordinary general shareholders' meeting resolves to approve the cancellation of the 875,000 Original Kreos Subscription Rights (as defined above), and in view of this cancellation to approve (i) the issuance of the 875,000 New Kreos Subscription Rights (as defined above) to the benefit of Kreos (and its permitted successors and assigns) (giving the holder the right to subscribe to new shares of the Company for an aggregate maximum issue price of EUR 875,000.00) exercisable at an exercise price per underlying new share equal to the lowest subscription price paid or agreed to be paid for a share in the share capital of the Company pursuant to any round of equity financing (or other financing convertible or exchangeable into equity) by the Company (taking into account any discounts including those arising on conversion or cancellation or indebtedness and/or interest thereon, but not taking into account any further anti-dilution adjustment mechanisms included in such rights or securities) prior to the exercise of the New Kreos Subscription Rights, and subject to certain exempted events (set out below in section (a)) that shall not be taken into account when determining the applicable exercise price per underlying new share, and (ii) dis-apply, in the interest of the Company and for the purposes of the issuance of the New Kreos Subscription Rights, the preferential subscription right of the existing shareholders of the Company and, as far as needed, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of Kreos (and its permitted successors and assigns). In view thereof, the extraordinary general shareholders' meeting resolves as follows:

- (a) Cancellation Original Kreos Subscription Rights: The Original Kreos Subscription Rights are cancelled.
- (b) Terms and conditions of the subscription rights: The terms and conditions of the New Kreos Subscription Rights shall be as set out in the annex to the report of the board of directors referred to in item 1(a) of the agenda (for the purpose of this resolution, the "**New Conditions**"), a copy of which shall remain attached to the minutes reflecting the present resolution. The main terms of the New Kreos Subscription Rights can, for information purposes, be summarised as follows:
 - (i) *Subscription rights for ordinary shares:* The 875,000 New Kreos Subscription Rights give the holder the right to subscribe to new shares of the Company for an aggregate maximum issue price of EUR 875,000.00 at an exercise price per underlying new share equal to the lowest subscription price paid or agreed to be paid for a share in the share capital of the Company pursuant to any round of equity financing (or other financing convertible or exchangeable into equity) by the Company (taking into account any discounts including those arising on conversion or cancellation or indebtedness and/or interest thereon, but not taking into account any further anti-dilution adjustment mechanisms

included in such rights or securities) prior to the exercise of the New Kreos Subscription Rights, provided, however, that any subscription or issue price paid, or agreed to be paid, in the framework of the following transactions shall not be considered when determining the aforementioned exercise price:

- (A) the issuance of new shares or other securities that, directly or indirectly, can be exercised, converted or exchanged for shares in the Company (and the issuance of shares pursuant to such exercise, conversion or exchange) within the framework of a share based incentive plan for members of the personnel as defined in article 1:27 of the Belgian Companies and Associations Code, whether issued, created or put in place before or after 8 July 2024; or
- (B) the issuance of new shares in the Company pursuant any of the other warrants or subscription rights issued by the Company prior to 8 July 2024.

The abovementioned exercise price per new share underlying the New Kreos Subscription Rights is subject to certain adjustments in case of any subdivision (or stock split) or consolidation (or reverse stock split), as set out in the New Conditions.

The abovementioned New Kreos Subscription Rights may be exercised in whole or in part, it being understood that New Kreos Subscription Rights cannot be exercised with respect to fractions of shares.

The New Conditions also provide that on one occasion only, in lieu of the payment in cash of the relevant aggregate exercise price for each of the relevant shares issuable, Kreos may in respect of all of the shares that would otherwise be issuable elect to receive a reduced number of shares, to be issued to Kreos as fully paid up, which reduced number of shares shall be determined in accordance with the formula included in New Condition 6.3.3 and described in the report of the board of directors referred to in item 1(a) of the agenda (the "**Net Issuance Exercise**"). In case of Net Issuance Exercise, the relevant shares will be issuable against an issue price equal to the fractional value of the Company's shares at that time (currently rounded EUR 0.1036 per share).

- (ii) *Duration:* The New Kreos Subscription Rights have an initial term commencing on the date on which the New Kreos Subscription Rights have been issued and expiring on 19 July 2027, at 12 a.m., or (if earlier) the completion of (i) a public takeover bid in respect of the Company's shares and other outstanding voting securities of the Company or securities granting access to voting rights, or (ii) a sale of the entire issued share capital of the Company to a bona fide third party on arm's length terms for cash consideration (a "**Share Sale**"). To the extent that the New Kreos Subscription Rights have not, or only partly, been exercised by 19 July 2027 and provided that no Share Sale has taken place prior to such expiry date, the Company will issue a number of new subscription rights calculated by subtracting the number of New Kreos Subscription Rights already exercised, at conditions that shall be *mutatis mutandis* the same as the New Conditions, for an additional period of two years. The aforementioned new subscription rights cannot be exercised prior to the expiry of the New Kreos Subscription Rights.

- (iii) *Transferability*: Kreos shall be entitled to transfer or assign the New Kreos Subscription Rights. Notwithstanding the foregoing, Kreos (i) should notify the Company of its intent to transfer the New Kreos Subscription Rights, and (ii) Kreos shall not be entitled to transfer the New Kreos Subscription Rights to an entity that is a customer, competitor or supplier of the Company or a group company, or an entity that holds 20% or more of the share capital of any such customer, competitor or supplier.
- (c) Underlying shares: The New Kreos Subscription Rights shall entitle the holder thereof to subscribe for new ordinary shares to be issued by the Company at the occasion of the exercise of the New Kreos Subscription Rights. The new ordinary shares shall be issued as fully paid up, shall have the same rights and benefits as, and rank *pari passu* in all respects, including as to entitlements to dividends and other distributions, with, the existing and outstanding ordinary shares of the Company at the moment of their issuance, and will be entitled to dividends and other distributions in respect of which the relevant record date or due date falls on or after the date of issue of the shares.
- (d) Disapplication of the preferential subscription right to the benefit of Kreos (and its permitted successors and assigns): The general shareholders' meeting resolves, in accordance with Articles 7:191 and 7:193 of the Belgian Companies and Associations Code, to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, as far as needed, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of Kreos (and its permitted successors and assigns), and to issue the New Kreos Subscription Rights to Kreos, as further explained in the report of the board of directors referred to in item 1(a) of the agenda.
- (e) Capital increase and allocation of the exercise price: Upon each exercise of the New Kreos Subscription Rights and the resulting issuance of new shares, the Company's share capital will be increased. Subject to, and in accordance with, the provisions of the New Conditions, upon exercise of the New Kreos Subscription Rights and issue of new shares, the aggregate amount of the applicable exercise price of the relevant New Kreos Subscription Rights will be allocated to the share capital of the Company. If the applicable issue price, per underlying new share issued, is greater than the fractional value of the existing shares immediately prior to the capital increase, then the applicable aggregate issue price shall be allocated in such a manner that per new share issued (i) a part of the applicable aggregate issue price equal to the fractional value of the existing shares immediately prior to the capital increase shall be booked as share capital, and (ii) the balance of the applicable aggregate issue price shall be booked as issue premium. This issue premium will be booked on a separate account as net equity on the liabilities side of the Company's balance sheet and can only be reduced in execution of a valid decision of the Company in accordance with the Belgian Companies and Associations Code. Following the issue of the new shares and the capital increase resulting therefrom, each of the shares (existing and new) shall represent the same fraction of the Company's share capital.
- (f) Powers of attorney: The board of directors is authorised to implement and execute the resolutions passed by the general shareholders' meeting in connection with the cancellation of the Original Kreos Subscription Rights and the issuance of the New Kreos Subscription Rights, and to take all steps and carry out all formalities that shall be required by virtue of the New Conditions of the New Kreos Subscription Rights, the Company's articles of association and applicable law in order to issue or transfer the shares upon exercise of the New Kreos Subscription Rights. Furthermore, each of the Company's directors and Fin-2K BV, represented by Kirsten Van Bockstaele

(*Chief Financial Officer*), each such person acting individually and with possibility of sub-delegation and the power of subrogation, shall have the power, upon exercise of the New Kreos Subscription Rights, (i) to proceed with the recording of (A) the capital increase and issue of new shares resulting from such exercise, (B) the allocation of the share capital and (as applicable) the issue premium, and (C) the amendment of the Company's articles of association in order to reflect the new share capital and number of outstanding shares following the exercise of the New Kreos Subscription Rights, (ii) to sign and deliver, on behalf of the Company, the relevant Euroclear, Euronext and bank documentation, the share register and all necessary documents in connection with the issuance and delivery of the shares to the beneficiary, and (iii) to do whatever may be necessary or useful (including but not limited to the preparation and execution of all documents and forms) for the admission of the shares issued upon the exercise of the New Kreos Subscription Rights to trading on the regulated market of Euronext Brussels (or such other markets on which the Company's shares will be trading at that time).

- (g) Approval in accordance with Article 7:151 of the Belgian Companies and Associations Code: The general shareholders' meeting resolves to take note, approve and ratify, insofar as required and applicable in accordance with Article 7:151 of the Belgian Companies and Associations Code, all clauses included in the New Conditions, which come into effect at the moment a change of control occurs and which fall or could be considered to fall within the scope of Article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company's assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it). The general shareholders' meeting grants a special power of attorney to each director of the Company, to the notary public Stijn Raes and to Fin-2K BV, represented by Kirsten Van Bockstaele (*Chief Financial Officer*), each acting alone and with power of substitution, for the purpose of carrying out the formalities required by Article 7:151 of the Belgian Companies and Associations Code with respect to this resolution.

Attendance quorum: According to the Belgian Companies and Associations Code, an attendance quorum of at least 50% of the outstanding shares must be present or represented at the extraordinary general shareholders' meeting for the deliberation and voting on the items of the aforementioned agenda of the extraordinary general shareholders' meeting. If such attendance quorum is not reached, a second extraordinary general shareholders' meeting will be convened for these agenda items, unless, as the case may be, decided otherwise on behalf of the board of directors, and the attendance quorum requirement will not apply to such second meeting.

Voting and majority: Subject to applicable legal provisions, each share shall have one vote. In accordance with applicable law, the proposed resolution referred to in the second item of the agenda of the extraordinary general shareholders' meeting shall be passed if it is approved by a majority of 75% of the votes validly cast by the shareholders. Pursuant to Article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to attend the extraordinary general shareholders' meeting, but only with an advisory vote.

PARTICIPATION TO THE MEETING

Introduction: Holders of securities issued by the Company that wish to participate to the extraordinary general shareholders' meeting of the Company should take into account the formalities and procedures described below.

Registration date: The registration date for the extraordinary general shareholders' meeting shall be Friday, 6 December 2024, at midnight (12:00 a.m., Belgian time). Only persons owning securities issued by the Company on Friday, 6 December 2024, at midnight (12:00 a.m., Belgian time) shall be entitled to participate to, and, as the case may be, vote at the extraordinary general shareholders' meeting. Only shareholders are entitled to vote. The holders of subscription rights can participate to the extraordinary general shareholders' meeting but only with an advisory vote. Shareholders, as well as holders of subscription rights must satisfy the formalities that are described under "*Participation to the meeting*".

Participation to the meeting: In order to be able to participate to the extraordinary general shareholders' meeting, a holder of securities issued by the Company must satisfy two conditions: (i) be registered as holder of such securities on the registration date, and (ii) notify the Company thereof, as described below:

- (i) **Registration:** Firstly, the right for a holder of securities issued by the Company to participate to and, as applicable, to vote at the extraordinary general shareholders' meeting is only granted on the basis of the registration of the securities concerned on the aforementioned registration date at midnight, via registration, in the applicable register book for the securities concerned (for registered securities) or in the accounts of a certified account holder or the relevant central securities depository for the securities concerned (for dematerialised securities).
- (ii) **Notification:** Secondly, in order to be admitted to the extraordinary general shareholders' meeting, the holders of securities issued by the Company must notify the Company that they want to participate to the meeting and must do so prior to or at the latest on Saturday, 14 December 2024. The holders of securities that wish to make such notification can make use of the registration notice form that can be obtained at the Company's registered office and on the Company's website (www.sequanamedical.com). The notice must reach the Company by mail at its registered office (Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium, Attention: Kirsten Van Bockstaele, Chief Financial Officer) or by e-mail at IR@sequanamedical.com at the latest on the sixth calendar day prior to the extraordinary general shareholders' meeting, *i.e.*, on or before Saturday, 14 December 2024 at the latest. For the holders of dematerialised securities, the notification should include a certificate confirming the number of securities that have been registered in their name on the registration date. The certificate can be obtained by the holders of the dematerialised securities with the certified account holder, the relevant central securities depository, or the relevant financial intermediary for the securities concerned.

Voting by mail: The shareholders can vote by mail in accordance with Article 37 of the Company's Articles of Association. Votes by mail must be cast by means of the form prepared by the Company. The voting by mail form can be obtained on the Company's website (www.sequanamedical.com). The voting by mail form must be signed in handwriting or electronically. If the possibility to sign the voting by mail form electronically is used, the electronic signature must be an electronic signature within the meaning of Article 3.10 of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended, or a qualified electronic signature within the meaning of Article 3.12 of the same Regulation. Signed voting by mail forms must reach the Company by mail at its registered office (Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium, Attention: Kirsten Van Bockstaele, Chief Financial Officer) or by e-mail at IR@sequanamedical.com, at the latest on the sixth calendar day prior to the extraordinary general shareholders' meeting, *i.e.*, on or before Saturday, 14 December 2024 at the latest. Holders of securities that wish to vote by mail must in any case comply with the formalities to participate to the meeting as explained under "*Participation to the meeting*".

Representation by proxy: The holders of securities can participate to the meeting and vote, as applicable, through a proxy holder. Proxy forms can be obtained at the Company's registered office and on the Company's website (www.sequanamedical.com). The proxy must be signed in handwriting or electronically. The electronic signature must meet the same requirements as the electronic signature for the voting by mail form (see also "*—Voting by mail*"). Signed proxies must reach the Company by mail at its registered office (Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium, Attention: Kirsten Van Bockstaele, Chief Financial Officer) or by e-mail at IR@sequanamedical.com, at the latest on the sixth calendar day prior to the extraordinary general shareholders' meeting, *i.e.*, on or before Saturday, 14 December 2024 at the latest. The appointment of a proxy holder must be made in accordance with the applicable rules of Belgian law, including in relation to conflicts of interest and the keeping of a register. Holders of securities that wish to be represented by proxy must, in any case comply with the formalities to participate to the meeting, as explained under "*—Participation to the meeting*".

Amendments to the agenda and additional proposed resolutions: Shareholders that alone or together with other shareholders hold at least 3% of the share capital of the Company have the right to put additional items on the agenda of the extraordinary general shareholders' meeting and to table draft resolutions in relation to items that have been or are to be included in the agenda. If the required attendance quorum for the agenda items concerned of the extraordinary general shareholders' meeting is not reached and a second extraordinary general shareholders' meeting is convened to deliberate and vote on such items, this right will not apply in relation to the agenda of the second extraordinary general shareholders' meeting. Shareholders wishing to exercise this right must prove on the date of their request that they own at least 3% of the outstanding shares. The ownership must be based, for dematerialised shares, on a certificate issued by the relevant central securities depository for the shares concerned, or by a certified account holder, confirming the number of shares that have been registered in the name of the relevant shareholders, and, for registered shares, on a certificate of registration of the relevant shares in the share register book of the Company. In addition, the shareholders concerned must, in any case, comply with the formalities to participate to the meeting, as explained under "*—Participation to the meeting*", with at least 3% of the outstanding shares. A request to put additional items on the agenda and/or to table draft resolutions must be submitted in writing, and must contain, in the event of an additional agenda item, the text of the agenda item concerned and, in the event of a draft resolution, the text of the draft resolution. The request must also mention the mail or e-mail address to which the Company will send the confirmation of receipt of the request. The request must reach the Company by mail at its registered office (Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium, Attention: Kirsten Van Bockstaele, Chief Financial Officer) or by e-mail at IR@sequanamedical.com at the latest on the twenty-second calendar day prior to the extraordinary general shareholders' meeting, *i.e.*, on or before Thursday, 28 November 2024 at the latest. In case of amendments to the agenda and additional proposed resolutions as aforementioned, the Company will publish an amended agenda with, as the case may be, additional agenda items and additional proposed resolutions no later than on the fifteenth calendar day prior to the extraordinary general shareholders' meeting, *i.e.*, on or before Thursday, 5 December 2024 at the latest. In addition, the Company shall make amended forms available for votes by mail and votes by proxy. Proxies and votes by mail that reach the Company prior to the publication of an amended agenda remain valid for the agenda items to which the proxies and votes by mail apply, subject, however, to applicable law and the further clarifications set out on the proxy forms and vote by mail forms.

Right to ask questions: Each holder of securities issued by the Company has the right to ask questions to the directors and the statutory auditor related to items on the agenda of a general shareholders' meeting. Questions can be asked during the meeting or can be submitted in writing prior to the meeting. Written questions must reach the Company by mail at its registered office (Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium, Attention: Kirsten Van Bockstaele, Chief Financial Officer) or by e-mail at IR@sequanamedical.com at the latest on the sixth calendar day prior to the extraordinary general shareholders' meeting, *i.e.*, on or before Saturday, 14 December 2024 at the latest. Written and oral questions will be answered during the meeting concerned in accordance with applicable law. In addition, in order for written questions to be considered, the

holders of securities issued by the Company that submitted the written questions concerned must comply with the formalities to participate to the meeting, as explained under "*—Participation to the meeting*" and/or under "*—Voting by mail*" or "*—Representation by proxy*".

Access to the meeting room: The natural persons that attend the extraordinary general shareholders' meeting in their capacity as owner of securities, holder of proxies or representative of a legal entity must be able to provide evidence of their identity in order to be granted access to the meeting room (subject to what is shared above under "*—General information*"). In addition, the representatives of legal entities must hand over the documents establishing their capacity as corporate representative or attorney-in-fact. These documents will be verified immediately before the start of the meeting.

Recommendation to use e-mail: The Company recommends the holders of its securities to use e-mail for all communication with the Company regarding the general shareholders' meeting. The Company's e-mail address for such communication is: IR@sequanamedical.com. The Company also points out that, in addition to being physically available at the Company's registered office and distributed by mail, all forms and other documentation in relation to the general shareholders' meeting will be available on the Company's website (www.sequanamedical.com). See also "*—Available documentation*".

DATA PROTECTION

The Company is responsible for the processing of personal data it receives from, or collects about, holders of securities issued by the Company and proxy holders in the context of general shareholders' meetings. The processing of such data will be carried out for the purposes of the organisation and conduct of the relevant general shareholders' meeting, including the convening notices, registrations, participation and voting, as well as for maintaining lists or registers of security holders, and the analysis of the investor and security holder base of the Company. The data include, amongst others, identification data, the number and nature of securities of a holder of securities issued by the Company, proxies and voting instructions. This data may also be transferred to third parties for the purposes of assistance or services to the Company in connection with the foregoing. The processing of such data will be carried out, mutatis mutandis, in accordance with the Company's Privacy & Cookie Policy, available on the Company's website (<https://www.sequanamedical.com/privacy-cookie-policy>). The Company draws the attention of the holders of securities issued by the Company and proxy holders to the description of the rights they may have as data subjects, such as, among others, the right to access, the right to rectify and the right to object to processing, which are outlined in the section 'Information regarding your rights' of the aforementioned Privacy & Cookie Policy. All this does not affect the rules that apply in connection with the registration and participation to the general shareholders' meeting. To exercise rights as a data subject and for all other information regarding the processing of personal data by or on behalf of the Company, the Company can be contacted by e-mail at dataprotection@sequanamedical.com.

AVAILABLE DOCUMENTATION

The following documentation is available on the Company's website (<https://www.sequanamedical.com/investors/shareholder-information>): the notice convening the extraordinary general shareholders' meeting, the agenda and proposed resolutions, or, if no resolutions are proposed, a commentary by the board of directors, updates of the agenda and proposed resolutions (in case of amendments to the agenda and proposed resolutions), the documents to be submitted to the extraordinary general shareholders' meeting as referred to in the agenda of the meeting, the attendance form, the vote by mail form, and the proxy form. Prior to the extraordinary general shareholders' meeting, holders of securities of the Company can also obtain at the registered office of the Company (Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium), free of cost, a copy of this documentation. The aforementioned website also mentions the total number of outstanding shares and voting rights of the Company.

On behalf of the board of directors,

THIS DOCUMENT IS NOT AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SHARES, SUBSCRIPTION RIGHTS OR OTHER SECURITIES OF SEQUANA MEDICAL NV. THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (DIRECTLY OR INDIRECTLY) IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL.